Login to Your Account

Financings Roundup

Apitope Raises €10M to Push its MS Drug to Phase II Trial

By Nuala Moran

Wednesday, October 29, 2008

No Abstract


BioWorld Today Correspondent

LONDON - Apitope Ltd. was forced to look beyond the UK to raise €10 million (US$12.5 million) from Belgian investors in its first formal venture capital funding round. The money will enable the company to carry out a Phase II proof-of-concept trial of its peptide-based immunotherapy for multiple sclerosis and to commercialize a diagnostic for identifying the disorder in its early stages.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription